FONTEYNE PAUL R. 4

What Happened

• Paul R. Fonteyne, a director of Amylyx Pharmaceuticals (AMLX), was granted a derivative equity award for 24,372 shares on June 4, 2026. The filing shows a $0.00 price per share (derivative award), meaning no cash purchase occurred at grant.
• This is an award (grant) to a board member rather than a market purchase or sale — a routine form of director compensation rather than an immediate bullish or bearish trade.

Key Details

• Transaction date: 2026-06-04; Form 4 filed 2026-06-08 (filed within the typical reporting window).
• Grant size/pricing: 24,372 shares; reported price $0.00 (derivative award).
• Shares owned after transaction: not specified in the provided excerpt of the filing.
• Footnote: The shares are subject to vesting and "shall vest in full upon the earlier of (i) June 4, 2027 or (ii) the date of the next annual meeting," contingent on Fonteyne's continuous service.
• No indication of a cashless exercise, sale, or tax-withholding reported in the excerpt.

Context

• Because this is a time‑vested derivative award (described in the filing as an "option" subject to future vesting), it does not represent an immediate purchase or sale of shares and should be viewed as compensation that vests with continued service.
• Such awards are common for directors and do not by themselves signal trading intent; they will only affect share ownership if/when the award vests and is converted or exercised.